Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 3Neoplasm Metastasis 2Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Interleukins × Clear all
NCT00994643 2025-04-30

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

Thomas Jefferson University

Phase 2 Completed
11 enrolled 9 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡